<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    8951257
   </pmid>
   <datecreated>
    <year>
     1997
    </year>
    <month>
     01
    </month>
    <day>
     03
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1997
    </year>
    <month>
     01
    </month>
    <day>
     03
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2004
    </year>
    <month>
     11
    </month>
    <day>
     17
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0031-4005
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       98
      </volume>
      <issue>
       6 Pt 1
      </issue>
      <pubdate>
       <year>
        1996
       </year>
       <month>
        Dec
       </month>
      </pubdate>
     </journalissue>
     <title>
      Pediatrics
     </title>
     <isoabbreviation>
      Pediatrics
     </isoabbreviation>
    </journal>
    <articletitle>
     Increased methylphenidate usage for attention deficit disorder in the 1990s.
    </articletitle>
    <pagination>
     <medlinepgn>
      1084-8
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To estimate the increased use and the prevalence of methylphenidate (Ritalin) treatment of youth with attention deficit disorder (ADD) during the 1990s.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Using time-trend findings from two large population-based data sources, three pharmaceutical databases, and one physician audit, a best-fit estimate of the usage and the usage trends for methylphenidate treatment over the half decade from 1990 through 1995 was sought.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      Five regions in the United States (US) and the nation as a whole.
     </abstracttext>
     <abstracttext label="PATIENTS" nlmcategory="METHODS">
      Youths on record as receiving methylphenidate for ADD.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      The findings from regional and national databases indicate that on average, there has been a 2.5-fold increase in the prevalence of methylphenidate treatment of youths with ADD between 1990 and 1995. In all, approximately 2.8% (or 1.5 million) of US youths aged 5 to 18 were receiving this medication in mid-1995. The increase in methylphenidate treatment for ADD appears largely related to an increased duration of treatment; more girls, adolescents, and inattentive youths on the medication; and a recently improved public image of this medication treatment.
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      The database findings presented serve to correct exaggerated media claims of a 6-fold expansion of methylphenidate treatment, although they do not clarify the issue of the appropriateness of this treatment.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Safer
      </lastname>
      <forename>
       D J
      </forename>
      <initials>
       DJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Zito
      </lastname>
      <forename>
       J M
      </forename>
      <initials>
       JM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Fine
      </lastname>
      <forename>
       E M
      </forename>
      <initials>
       EM
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     Pediatrics
    </medlineta>
    <nlmuniqueid>
     0376422
    </nlmuniqueid>
    <issnlinking>
     0031-4005
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Sympathomimetics
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      113-45-1
     </registrynumber>
     <nameofsubstance>
      Methylphenidate
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Pediatrics. 1997 Oct;100(4):730-1
     </refsource>
     <pmid version="1">
      9333759
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Attention Deficit Disorder with Hyperactivity
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child, Preschool
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Utilization
     </descriptorname>
     <qualifiername majortopicyn="N">
      trends
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N" type="Geographic">
      Maryland
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Methylphenidate
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pharmacoepidemiology
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prevalence
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Sympathomimetics
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1996
     </year>
     <month>
      12
     </month>
     <day>
      1
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1996
     </year>
     <month>
      12
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1996
     </year>
     <month>
      12
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     8951257
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

